ANDA 204305, held by Teva Pharms USA Inc. Ethinyl Estradiol; Etonogestrel.
As of Nov 16, 2026, ANDA 204305 (Ethinyl Estradiol; Etonogestrel), held by Teva Pharms USA Inc, was first approved by FDA on Jan 13, 2021, with 1 approved supplement and 0 published complete response letters.
FOR VAGINAL USE ONLY Etonogestrel and ethinyl estradiol vaginal ring is indicated for use by females of reproductive age to prevent pregnancy. Etonogestrel and ethinyl estradiol vaginal ring is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 13, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ethinyl Estradiol; Etonogestrel0.015MG/24HR;0.12MG/24HR · ring;vaginal | Ethinyl Estradiol; Etonogestrel | Rx |
| Apr 5, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 13, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters